FDA Appointments and Resignations
FDA Appointments and Resignations
It has been a week of turnover at the US Food and Drug Administration (Rockville, MD). Here is a chronology:
Sept. 22. Acting Center for Drug Evaluation and Research (CDER) Deputy Director Douglas Throckmorton appointed to the post permanently.
Sept. 23. FDA Commissioner Lester Crawford resigns. A copy of the resignation is distributed without comment to the media at 4:35 P.M. (The New York Times observes that the timing, late Friday afternoon with a Category 5 hurricane bearing down on the Texas coast, seems intended to reduce reaction.)
Sept. 23. President George Bush names National Cancer Institute Director Andrew C. von Eschenbach, MD, acting FDA commissioner.
Sept. 26. FDA reports that Jonathan Wilkin, director of the Division of Dermatology and Dental Products, is retiring and that deputy director Stanka Kukich would be named acting director.
Sept 26. Hsien-Ming James Hung named director of the Division of Biometrics I, in CDER’s Office of Pharmacoepidemiology and Statistical Science.
–Douglas McCormick
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
